TREATMENT OR PROPHYLAXIS OF DEMENTIA, NEURODEGENERATIVE DISORDERS, SCHIZOPHRENIA, ADHD, SOMNOLENCE OR EPILEPSY

摘要

The present invention relates to the use of 1 -{6-[(3-cyclobutyl-2,3,4,5-tetrahydro- 1 H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone (Formula (I)) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of dementia and/or a neurodegenerative disease (e.g. Alzheimer's disease, in particular cognitive impairment therein), schizophrenia (e.g. cognitive impairment associated therewith), attention deficit hyperactivity disorder, somnolence, or epilepsy, in a human, by oral administration to the human using an escalating dosage regimen comprising: - an initial dosage regimen of from 2 to 15 micrograms (preferably from 5 to 10 micrograms) of the 1 -{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7- yl)oxy]-3-pyridinyl}-2-pyrrolidinone or the pharmaceutically acceptable salt thereof (measured as the free base), administered orally once per day, and subsequently - a maintenance dosage regimen of from 30 to 150 micrograms (preferably from from 40 to 80 micrograms) of the 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3- benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone or the pharmaceutically acceptable salt thereof (measured as the free base), administered orally once per day.